Switch theme
Sign up to access all valuation multiples
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
2017
229
LTM Revenue $18K
LTM EBITDA -$247M
$57.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Allogene Therapeutics has a last 12-month revenue (LTM) of $18K and a last 12-month EBITDA of -$247M.
In the most recent fiscal year, Allogene Therapeutics achieved revenue of $22K and an EBITDA of -$243M.
Allogene Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Allogene Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $18K | XXX | $22K | XXX | XXX | XXX |
| Gross Profit | $18K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$247M | XXX | -$243M | XXX | XXX | XXX |
| EBITDA Margin | -1341551% | XXX | -1106032% | XXX | XXX | XXX |
| EBIT | -$258M | XXX | -$257M | XXX | XXX | XXX |
| EBIT Margin | -1402927% | XXX | -1170373% | XXX | XXX | XXX |
| Net Profit | -$245M | XXX | -$258M | XXX | XXX | XXX |
| Net Margin | -1329959% | XXX | -1170864% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Allogene Therapeutics's stock price is $1.
Allogene Therapeutics has current market cap of $256M, and EV of $57.2M.
See Allogene Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $57.2M | $256M | XXX | XXX | XXX | XXX | $-1.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Allogene Therapeutics has market cap of $256M and EV of $57.2M.
Allogene Therapeutics's trades at 2598.4x EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Allogene Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Allogene Therapeutics has a P/E ratio of -1.0x.
See valuation multiples for Allogene Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $256M | XXX | $256M | XXX | XXX | XXX |
| EV (current) | $57.2M | XXX | $57.2M | XXX | XXX | XXX |
| EV/Revenue | 3104.3x | XXX | 2598.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3104.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAllogene Therapeutics's last 12 month revenue growth is -21%
Allogene Therapeutics's revenue per employee in the last FY averaged $0K, while opex per employee averaged $1.1M for the same period.
Allogene Therapeutics's rule of 40 is -316119% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Allogene Therapeutics's rule of X is -1341603% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Allogene Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -21% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Margin | -1341551% | XXX | -1106032% | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -316119% | XXX | -1106053% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1341603% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 874086% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1170473% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Allogene Therapeutics acquired XXX companies to date.
Last acquisition by Allogene Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Allogene Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Allogene Therapeutics founded? | Allogene Therapeutics was founded in 2017. |
| Where is Allogene Therapeutics headquartered? | Allogene Therapeutics is headquartered in United States of America. |
| How many employees does Allogene Therapeutics have? | As of today, Allogene Therapeutics has 229 employees. |
| Who is the CEO of Allogene Therapeutics? | Allogene Therapeutics's CEO is Dr. David D. Chang, M.D.,PhD. |
| Is Allogene Therapeutics publicy listed? | Yes, Allogene Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Allogene Therapeutics? | Allogene Therapeutics trades under ALLO ticker. |
| When did Allogene Therapeutics go public? | Allogene Therapeutics went public in 2018. |
| Who are competitors of Allogene Therapeutics? | Similar companies to Allogene Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Allogene Therapeutics? | Allogene Therapeutics's current market cap is $256M |
| What is the current revenue of Allogene Therapeutics? | Allogene Therapeutics's last 12 months revenue is $18K. |
| What is the current revenue growth of Allogene Therapeutics? | Allogene Therapeutics revenue growth (NTM/LTM) is -21%. |
| What is the current EV/Revenue multiple of Allogene Therapeutics? | Current revenue multiple of Allogene Therapeutics is 3104.3x. |
| Is Allogene Therapeutics profitable? | Yes, Allogene Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Allogene Therapeutics? | Allogene Therapeutics's last 12 months EBITDA is -$247M. |
| What is Allogene Therapeutics's EBITDA margin? | Allogene Therapeutics's last 12 months EBITDA margin is -1341551%. |
| What is the current EV/EBITDA multiple of Allogene Therapeutics? | Current EBITDA multiple of Allogene Therapeutics is -0.2x. |
| What is the current FCF of Allogene Therapeutics? | Allogene Therapeutics's last 12 months FCF is -$212M. |
| What is Allogene Therapeutics's FCF margin? | Allogene Therapeutics's last 12 months FCF margin is -1151422%. |
| What is the current EV/FCF multiple of Allogene Therapeutics? | Current FCF multiple of Allogene Therapeutics is -0.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
